Navigation Links
TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
Date:7/14/2008

HOUSTON, TX Scientists from The University of Texas M. D. Anderson Cancer Center have found overexpression of tissue type transglutaminase (TG2) in ovarian cancer is associated with increased tumor cell growth and adhesion, resistance to chemotherapy and lower overall survival rates. When researchers targeted and silenced TG2 in animal models, cancer progression was reversed, suggesting the protein may also provide a novel therapeutic approach for late-stage ovarian cancer.

These findings in the July 15th issue of Cancer Research by a team of researchers led by Anil K. Sood, M.D., professor in the Departments of Gynecologic Oncology and Cancer Biology, and Kapil Mehta, Ph.D., professor in the Department of Experimental Therapeutics at M. D. Anderson, are among the first to explore TG2's functionality in ovarian cancer.

"TG2 appears to fuel different types of cancer through multiple molecular pathways, making it an important therapeutic target," said Mehta, whose lab also has connected TG2 overexpression to drug-resistant and metastatic melanoma, breast cancer and pancreatic cancer.

"Drug resistance and metastasis are major impediments to the successful treatment of ovarian cancer and until now we had little information about the role TG2 played in ovarian cancer," Sood said. "We began to see its story unfold as we translated this data from tissue samples to cell lines to animal models."

The American Cancer Society estimates 15,000 U.S. women will die from ovarian cancer this year. Most patients present with advanced stage disease that has spread beyond the primary tumor site. More than 70 percent of ovarian cancer patients will suffer a recurrence and eventually succumb to the disease.

Higher TG2, lower survival

The study, which examined 93 ovarian cancer samples of ranging stages, found that high levels of TG2 corresponded with significantly lower patient survival than those with lo
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New study shows greenback cutthroat trout involved in recovery effort misidentified
2. Brain network related to intelligence identified
3. The reservoir of Marburg virus identified in a species of fruit bat
4. Genes that both extend life and protect against cancer identified
5. Genes identified to protect brassicas from damaging disease
6. Newly-identified exercise gene could help with depression
7. Best treatment identified to reduce deadly Staph infections
8. New approach for attacking lupus identified
9. Mutant gene identified as villain in hardening of the arteries
10. Cognitive, genetic clues identified in imaging study of alcohol addiction
11. Novel mechanism for long-term learning identified by Carnegie Mellon researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... O R I M M E D I A ... E CELL TRANSPLANTATION,The Regenerative Medicine Journal Stem cells derived ... animal models of lung disease Tampa, Fla. (Aug. 24, ... Transplantation (20:6), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , highlight the ...
... 1.3 million). That is a new, estimated total number ... offered -- with 6.5 million species found on land and ... the ocean depths. Announced today by Census of Marine ... analytical technique that dramatically narrows the range of previous estimates. ...
... CHAMPAIGN, Ill. A new physics-based theory could give ... of liquids composed of large polymers. This advance provides ... fast-flow, high-stress processing conditions for plastics and other polymeric ... Margaret H. Professor of materials science and engineering at ...
Cached Biology News:Stem cells derived from human amniotic fluid hold promise 2Stem cells derived from human amniotic fluid hold promise 3How many species on Earth? 8.7 million 2How many species on Earth? 8.7 million 3How many species on Earth? 8.7 million 4How many species on Earth? 8.7 million 5New theory may shed light on dynamics of large-polymer liquids 2
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
(Date:7/29/2015)... ... 29, 2015 , ... G-CON Manufacturing, Inc., the leading prefabricated ... generation cell therapy POD® design. The 2nd generation portfolio not only delivers design ... POD® design. , “G-CON first offered our miniPOD CT product line to ...
Breaking Biology Technology:Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3
... Realty Trust, Inc.,(NYSE: BMR ) today announced the ... property in Seattle, Washington. A wholly owned subsidiary of ... diabetes care, has,agreed to lease 36,900 square feet, anchoring ... market., Commenting on the project, Don Foster, Corporate ...
... Inc. (OTC,Bulletin Board: TBIO) announces the following Webcast:, What: ... Conference Call, When: ... http://www.transgenomic.com/events.asp?id=6 , How: Live ... address above., ...
... NicOx,S.A. (Euronext Paris: COX) today reported financial results for the ... third quarter of 2008:, - Positive top-line results from the ... three co-primary efficacy endpoints at week-13 (p naproxcinod ... non-inferiority to naproxen 500 mg bid at week-13 and ...
Cached Biology Technology:BioMed Realty Trust Announces 36,900 Square Foot Lease in Seattle With Novo Nordisk 2BioMed Realty Trust Announces 36,900 Square Foot Lease in Seattle With Novo Nordisk 3Webcast Alert: Transgenomic Inc. Announces Third Quarter 2008 Earnings Release Conference Call Webcast 2NicOx Reports Results for the First Three Quarters of 2008 2NicOx Reports Results for the First Three Quarters of 2008 3NicOx Reports Results for the First Three Quarters of 2008 4NicOx Reports Results for the First Three Quarters of 2008 5NicOx Reports Results for the First Three Quarters of 2008 6NicOx Reports Results for the First Three Quarters of 2008 7NicOx Reports Results for the First Three Quarters of 2008 8NicOx Reports Results for the First Three Quarters of 2008 9NicOx Reports Results for the First Three Quarters of 2008 10
Human PLUNC MAb (Clone 252512)...
... Rabbit polyclonal to GRASP1 ( ... Antigen: Synthetic ... from the C terminal region of ... hemocyanin (KLH). Entrez ...
Homo sapiens CDC23 (cell division cycle 23, yeast, homolog),...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Biology Products: